Logo image of LYEL

LYELL IMMUNOPHARMA INC (LYEL) Stock Fundamental Analysis

NASDAQ:LYEL - Nasdaq - US55083R1041 - Common Stock - Currency: USD

0.7007  +0.04 (+6.17%)

After market: 0.7006 0 (-0.01%)

Fundamental Rating

3

Overall LYEL gets a fundamental rating of 3 out of 10. We evaluated LYEL against 571 industry peers in the Biotechnology industry. LYEL has a great financial health rating, but its profitability evaluates not so good. LYEL has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year LYEL has reported negative net income.
In the past year LYEL has reported a negative cash flow from operations.
LYEL had negative earnings in each of the past 5 years.
In the past 5 years LYEL reported 4 times negative operating cash flow.
LYEL Yearly Net Income VS EBIT VS OCF VS FCFLYEL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 0 -50M -100M -150M -200M -250M

1.2 Ratios

LYEL has a better Return On Assets (-32.94%) than 64.12% of its industry peers.
LYEL has a better Return On Equity (-38.44%) than 72.65% of its industry peers.
Industry RankSector Rank
ROA -32.94%
ROE -38.44%
ROIC N/A
ROA(3y)-24.34%
ROA(5y)-23.76%
ROE(3y)-28.24%
ROE(5y)-28.98%
ROIC(3y)N/A
ROIC(5y)N/A
LYEL Yearly ROA, ROE, ROICLYEL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -10 -20 -30

1.3 Margins

LYEL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LYEL Yearly Profit, Operating, Gross MarginsLYEL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -50K -100K -150K

More info and screens

7

2. Health

2.1 Basic Checks

LYEL does not have a ROIC to compare to the WACC, probably because it is not profitable.
LYEL has more shares outstanding than it did 1 year ago.
There is no outstanding debt for LYEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LYEL Yearly Shares OutstandingLYEL Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M
LYEL Yearly Total Debt VS Total AssetsLYEL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

2.2 Solvency

LYEL has an Altman-Z score of -1.57. This is a bad value and indicates that LYEL is not financially healthy and even has some risk of bankruptcy.
LYEL has a Altman-Z score (-1.57) which is in line with its industry peers.
There is no outstanding debt for LYEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.57
ROIC/WACCN/A
WACC9.44%
LYEL Yearly LT Debt VS Equity VS FCFLYEL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 200M -200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 13.43 indicates that LYEL has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 13.43, LYEL belongs to the top of the industry, outperforming 86.68% of the companies in the same industry.
LYEL has a Quick Ratio of 13.43. This indicates that LYEL is financially healthy and has no problem in meeting its short term obligations.
LYEL has a Quick ratio of 13.43. This is amongst the best in the industry. LYEL outperforms 86.68% of its industry peers.
Industry RankSector Rank
Current Ratio 13.43
Quick Ratio 13.43
LYEL Yearly Current Assets VS Current LiabilitesLYEL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 200M 400M 600M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for LYEL have decreased strongly by -27.42% in the last year.
Looking at the last year, LYEL shows a very negative growth in Revenue. The Revenue has decreased by -99.87% in the last year.
Measured over the past years, LYEL shows a very negative growth in Revenue. The Revenue has been decreasing by -74.41% on average per year.
EPS 1Y (TTM)-27.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-99.87%
Revenue growth 3Y-74.41%
Revenue growth 5YN/A
Sales Q2Q%36%

3.2 Future

The Earnings Per Share is expected to grow by 9.70% on average over the next years. This is quite good.
The Revenue is expected to decrease by -68.45% on average over the next years. This is quite bad
EPS Next Y-2%
EPS Next 2Y4.46%
EPS Next 3Y9.7%
EPS Next 5YN/A
Revenue Next Year-98.94%
Revenue Next 2Y-41.42%
Revenue Next 3Y-68.45%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
LYEL Yearly Revenue VS EstimatesLYEL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M
LYEL Yearly EPS VS EstimatesLYEL Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

LYEL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LYEL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LYEL Price Earnings VS Forward Price EarningsLYEL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LYEL Per share dataLYEL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.46%
EPS Next 3Y9.7%

More info and screens

0

5. Dividend

5.1 Amount

LYEL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LYELL IMMUNOPHARMA INC

NASDAQ:LYEL (2/21/2025, 8:00:00 PM)

After market: 0.7006 0 (-0.01%)

0.7007

+0.04 (+6.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)02-26 2025-02-26/amc
Inst Owners57.34%
Inst Owner Change-99.21%
Ins Owners0.14%
Ins Owner Change0%
Market Cap204.72M
Analysts46.67
Price Target0.82 (17.03%)
Short Float %4.96%
Short Ratio9.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.29%
Min EPS beat(2)13.92%
Max EPS beat(2)16.67%
EPS beat(4)3
Avg EPS beat(4)8.13%
Min EPS beat(4)-12.04%
Max EPS beat(4)16.67%
EPS beat(8)7
Avg EPS beat(8)26.1%
EPS beat(12)10
Avg EPS beat(12)21.02%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-20%
PT rev (3m)-60%
EPS NQ rev (1m)7.27%
EPS NQ rev (3m)7.27%
EPS NY rev (1m)0%
EPS NY rev (3m)6.87%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)175%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3249.47
P/FCF N/A
P/OCF N/A
P/B 0.39
P/tB 0.39
EV/EBITDA N/A
EPS(TTM)-0.79
EYN/A
EPS(NY)-0.71
Fwd EYN/A
FCF(TTM)-0.53
FCFYN/A
OCF(TTM)-0.53
OCFYN/A
SpS0
BVpS1.82
TBVpS1.82
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -32.94%
ROE -38.44%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-24.34%
ROA(5y)-23.76%
ROE(3y)-28.24%
ROE(5y)-28.98%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.27%
Cap/Sales 707.94%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.43
Quick Ratio 13.43
Altman-Z -1.57
F-Score2
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)209.64%
Cap/Depr(5y)620.54%
Cap/Sales(3y)903.28%
Cap/Sales(5y)1161.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-27.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-2%
EPS Next 2Y4.46%
EPS Next 3Y9.7%
EPS Next 5YN/A
Revenue 1Y (TTM)-99.87%
Revenue growth 3Y-74.41%
Revenue growth 5YN/A
Sales Q2Q%36%
Revenue Next Year-98.94%
Revenue Next 2Y-41.42%
Revenue Next 3Y-68.45%
Revenue Next 5YN/A
EBIT growth 1Y-7.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year24.02%
EBIT Next 3Y3.85%
EBIT Next 5YN/A
FCF growth 1Y18.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.13%
OCF growth 3YN/A
OCF growth 5YN/A